A Phase 1, Open Label, Single Arm Study To Establish The Safety Of Administering CP 675,206 As A One Hour Infusion In Patients With Surgically Incurable Stage III Or Stage IV Melanoma.

Trial Profile

A Phase 1, Open Label, Single Arm Study To Establish The Safety Of Administering CP 675,206 As A One Hour Infusion In Patients With Surgically Incurable Stage III Or Stage IV Melanoma.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2012

At a glance

  • Drugs Tremelimumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Jun 2012 Company added in the association field and additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 24 Feb 2010 Actual patient numbers amended from 45 to 49 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top